The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Current unanswered questions in segmentectomy for lung cancer
Rene Petersen, MD, PhD, Rigshospitalet, Copenhagen, Denmark, highlights the growing interest in segmentectomy following the publication of the JCOG0802 and CALGB 140503 (NCT00499330) trials, which demonstrated comparable survival rates to lobectomy for early-stage lung cancer. However, despite the increased adoption of segmentectomy, there are still significant knowledge gaps that need to be addressed. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
